自闭症谱系障碍治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Autism Spectrum Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月28日 | 出版商:

Global Market Insights Inc. | 英文 231 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球自闭症谱系障碍(ASD) 治疗市场估值为341 亿美元，预计2024 年至2032 年复合年增长率为4.8%。盛行率的上升，诊断标准的提高、意识的提高和遗传影响越来越多地影响疾病。

随着自闭症谱系障碍意识的提高，越来越多的人接受诊断，刺激了全球对有效治疗的需求。例如，美国疾病管制与预防中心 (CDC) 报告称，美国大约每 54 名儿童中就有 1 名被诊断患有自闭症谱系障碍 (ASD)，这标誌着过去十年诊断率显着上升。这种诊断激增促进了治疗方法的创新，导致行为疗法、药理学解决方案和数位疗法的创建，进一步推动市场成长。

诊断工具的进步有助于 ASD 治疗产业的发展。随着这些技术的发展，它们增强了更早检测 ASD 的能力，从而导致更多的诊断。确诊病例的增加扩大了治疗需求，推动了市场扩张。此外，医疗保健专业人员和家长意识的提高，加上先进的诊断工具，导致 ASD 筛检和诊断的增加。这尤其重要，因为它引起了人们对先前诊断不足的病例的关注，拓宽了自闭症谱系障碍治疗的市场。

整个产业分为治疗类型、疾病、年龄层、最终用途和地区。

市场依治疗类型分为药物、治疗和辅助应用。药物类别包括抗精神病药物、选择性血清素再摄取抑制剂、兴奋剂等。治疗部分包括行为和沟通疗法、螯合疗法等。 2023年，药品板块引领市场，估值达168亿美元。这部分对于管理自闭症谱系障碍相关症状至关重要，包括行为挑战和沟通问题，以及焦虑等併发病症。

自闭症谱系障碍（ASD）治疗市场将疾病分为自闭症、亚斯伯格症、广泛性发展障碍（PDD）等。 2023 年，自闭症细分市场占据 52.2% 的主导市场。该细分市场对于满足自闭症挑战更严重的个人的需求至关重要。这里的治疗结合了行为疗法、药理学方法和支持服务，所有这些都旨在改善生活品质和发育结果。

自闭症谱系障碍治疗市场按年龄分为儿童和成人。 2023年，儿童细分市场以253亿美元的估值处于领先地位。这种主导地位归因于认识的提高、及时的诊断以及儿童自闭症谱系障碍盛行率的不断上升。儿童的治疗途径包括行为疗法、沟通策略、教育措施和药物监督。其中，行为疗法，尤其是应用行为分析脱颖而出，强调透过强化技术来提高技能。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Service Provider
Medication Manufacturer

简介目录

Product Code: 11087

The Global Autism Spectrum Disorder (ASD) Treatment Market was valued at USD 34.1 billion in 2023 and is projected to grow at a CAGR of 4.8% from 2024 to 2032. Several factors drive this market growth, notably the rising prevalence of ASD, which is increasingly shaped by enhanced diagnostic criteria, growing awareness, and genetic influences.

As awareness of ASD rises, more individuals receive diagnoses, fueling a global demand for effective treatments. For example, the Centers for Disease Control and Prevention (CDC) reports that about 1 in 54 children in the U.S. is diagnosed with ASD, marking a notable uptick in diagnosis rates over the last decade. This diagnostic surge has catalyzed innovations in treatment methods, leading to the creation of behavioral therapies, pharmacological solutions, and digital therapeutics, further propelling market growth.

Advancements in diagnostic tools help in the growth of the ASD treatment industry. As these technologies evolve, they enhance the ability to detect ASD earlier, resulting in more diagnoses. This uptick in diagnosed cases amplifies the demand for treatments, fueling market expansion. Moreover, increased awareness among healthcare professionals and parents, coupled with advanced diagnostic tools, has led to a rise in screenings and diagnoses of ASD. This is especially significant as it brings attention to previously underdiagnosed cases, broadening the market for ASD treatments.

The overall industry is divided into treatment type, disease, age group, end-use, and region.

The market is categorized by treatment type into drugs, therapy, and assistive applications. Within the drugs category, there are antipsychotic drugs, selective serotonin reuptake inhibitors, stimulants, and others. The therapy segment includes behavior and communication therapies, chelation therapy, and more. In 2023, the drugs segment led the market, achieving a valuation of USD 16.8 billion. This segment is vital for managing ASD-related symptoms, including behavioral challenges and communication issues, as well as co-occurring conditions like anxiety.

ASD treatment market categorizes diseases into autistic disorder, Asperger syndrome, pervasive developmental disorder (PDD), and others. In 2023, the autistic disorder segment held a dominant market share of 52.2%. This segment is essential for catering to individuals with more pronounced autism challenges. Treatments here combine behavioral therapies, pharmacological methods, and supportive services, all aimed at improving life quality and developmental results.

Autism spectrum disorder treatment market segments by age into children and adults. In 2023, the children segment led with a valuation of USD 25.3 billion. This dominance is attributed to heightened awareness, timely diagnoses, and a growing prevalence of ASD in children. Treatment avenues for children encompass behavioral therapies, communication strategies, educational initiatives, and medication oversight. Among these, behavioral therapies, especially applied behavior analysis, stand out, emphasizing skill enhancement through reinforcement techniques.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of autism
  - 3.2.1.2 Advancements in diagnostic tools
  - 3.2.1.3 Innovation in therapeutics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Variability in treatment efficacy
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Drugs
- 5.2.1 Antipsychotic drugs
- 5.2.2 Selective serotonin reuptake inhibitors
- 5.2.3 Stimulants
- 5.2.4 Other drugs
5.3 Therapy
- 5.3.1 Behavior and communication therapies
- 5.3.2 Chelation therapy
- 5.3.3 Other therapies
5.4 Assistive apps

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Autistic disorder
6.3 Asperger syndrome
6.4 Pervasive developmental disorder (PDD)
6.5 Other diseases

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Children
7.3 Adult

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Homecare settings
8.4 Rehabilitation centers
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Service Provider
- 10.1.1 Autism Research Institute
- 10.1.2 Child Mind Institute, Inc.
- 10.1.3 Cleveland Clinic
- 10.1.4 Mayo Foundation for Medical Education and Research (MFMER).
- 10.1.5 The General Hospital Corporation
10.2 Medication Manufacturer
- 10.2.1 Axial Therapeutics Inc.
- 10.2.2 Bristol - Myers Squibb Company
- 10.2.3 Curemark LLC
- 10.2.4 Eli Lilly and Company
- 10.2.5 F. Hoffmann - La Roche Ltd.
- 10.2.6 Johnson and Johnson Services, Inc.
- 10.2.7 Novartis AG
- 10.2.8 Otsuka Pharmaceutical Co., Ltd.
- 10.2.9 PaxMedica
- 10.2.10 Pfizer Inc